-Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

Media coverage

• Title	-Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
  Media name/outlet	M2 PressWIRE
  Country/Territory	United States
  Date	3/10/23
  Persons	Leon Kircik

• Title	-Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	3/10/23
  Persons	Leon Kircik